Zobrazeno 41 - 50
of 108
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Naomi B. Haas, Xiaowei Xu, Phyllis A. Gimotty, Jennifer J.D. Morrissette, Lynn M. Schuchter, Shujing Liu, Giorgos C. Karakousis, Anna C. Pavlick, Michael A. Davies, Khalida Wani, Hussein Tawbi, Tara C. Gangadhar, Jeffrey A. Sosman, Ravi K. Amaravadi, Meghan Buckley, Michael T. Tetzlaff, Clinton Yam, Luke Walker, Ragini R. Kudchadkar, Jianhua Zhao, Wanleng Deng
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(1)
Purpose: The objectives of the study were to evaluate the safety of daily oral PX-866 in combination with twice daily vemurafenib and to identify potential predictive biomarkers for this novel combination. Experimental Design: We conducted a phase I,
Autor:
Susan N. Thomas, Brian Pollack, Gregory B. Lesinski, Yun Min Chang, Maiko Sasaki, Edmund K. Waller, Anna E. Kersh, Haydn T. Kissick, Spencer Ng, Ragini R. Kudchadkar
Publikováno v:
Journal of clinical pharmacology. 58(1)
Two pharmacologic approaches that are currently at the forefront of treating advanced cancer are those that center on disrupting critical growth/survival signaling pathways within tumor cells (commonly referred to as "targeted therapies") and those t
Autor:
Geoffrey T. Gibney, Ragini R. Kudchadkar, Alexander R. A. Anderson, Vernon K. Sondak, Silvya Stuchi Maria-Engler, Renato Ramos Massaro, Jane L. Messina, Eunjung Kim, Inna V. Fedorenko, Ravi K. Amaravadi, Vito W. Rebecca, Keiran S.M. Smalley
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
This study investigates the mechanism of action behind the long-term responses (12–16 months) of two BRAF WT melanoma patients to the AKT inhibitor MK-2206 in combination with paclitaxel and carboplatin. Although single agent MK-2206 inhibited phos
Autor:
Joseph Markowitz, Zeynep Eroglu, Y. Ann Chen, Jeffrey S. Weber, Andrew S. Brohl, Ragini R. Kudchadkar, Nikhil I. Khushalani, Ram Thapa
Publikováno v:
Journal for Immunotherapy of Cancer
Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase I
Autor:
Brian Olson, Michael C. Lowe, Maurice Zauderer, Desa Rae Pastore, Crystal Mallow, Conor E. Steuer, John E. Leonard, Ernest S. Smith, Elizabeth E. Evans, Gregory B. Lesinski, Nabil F. Saba, Christina Wu, Ragini R. Kudchadkar, Terrence L. Fisher
Publikováno v:
Cancer Research. 79:CT016-CT016
Interrogation of the tumor microenvironment (TME) is crucial to provide insight into biological activity, resistance mechanisms and implementation of rational combination immunotherapies. Semaphorin 4D (SEMA4D, CD100) has broad immunomodulatory effec
Autor:
Rikesh Patel, Jing Su, Robert H. Press, David H. Lawson, Hiao-Rong Chen, Tahseen H. Nasti, Andre J. Burnham, Jeffrey J. Olson, Alexandra Ross, Ragini R. Kudchadkar, Soma Sengupta, Jeanne Kowalski, Daniel Pomeranz Krummel, Stewart G. Neill, Michael D. Chan, Matthew Schniederjan, Cory Adamson, Maxwell Xu, Laura Kallay, Havva Keskin, Erin Connelly, Walter J. Curran, Mohammad K. Khan, Manali Rupji, Lindsey Lowder, Havi Rosen, Benjamin Izar, Milota Kaluzova
Publikováno v:
Cancer Research. 79:247-247
Primary cutaneous melanoma is often successfully treated in early stages in patients with regional disease. While distant metastatic disease, including brain metastasis, that develops in most stage IV melanoma patients, carries a particularly poor pr
Autor:
Bassel F. El-Rayes, Walid L. Shaib, Bradley C. Carthon, Haydn T. Kissick, David H. Lawson, R. Donald Harvey, Mehmet Akce, Colleen Lewis, Viraj A. Master, Christina Wu, Yuan Liu, Mehmet Asim Bilen, Rathi N. Pillai, Julie M. Shabto, Ragini R. Kudchadkar, Hannah Collins, Suresh S. Ramalingam, Taofeek K. Owonikoko, Olatunji B. Alese, Dylan J. Martini, Conor E. Steuer
Publikováno v:
Cancer Immunology Research. 7:B176-B176
Background: There are now six approved immune checkpoint inhibitors for several different malignancies including melanoma, head and neck cancer, lung cancer, and renal cell carcinoma. Given the increased number of available immunotherapeutic agents,
Autor:
David H. Lawson, Jeffrey J. Olson, Jing Su, Robert H. Press, Alexandra Ross, Daniel Pomeranz Krummel, Matthew Schniederjan, Ragini R. Kudchadkar, Havva Keskin, Laura Kallay, Erin Connelly, Jeanne Kowalski, Maxwell Xu, Walter J. Curran, Mohammad K. Khan, Michael D. Chan, Manali Rupji, Soma Sengupta, Lindsey Lowder, Bhakti Dwivedi, Cory Adamson, Rikesh Patel, Stewart G. Neill, Havi Rosen, Benjamin Izar
Publikováno v:
Neuro-Oncology. 20:vi68-vi68
Brain metastases are the most common cause of adult brain tumors and highly challenging to treat. Additionally, melanoma brain metastases carry a particularly poor prognosis, with a median overall survival of 4–5 months. Standard-of-care treatment
Autor:
Olatunji B. Alese, Walid L. Shaib, Ragini R. Kudchadkar, Dylan J. Martini, S.S. Ramalingam, Bassel F. El-Rayes, Mehmet Asim Bilen, Yingzi Liu, David H. Lawson, Bradley C. Carthon, Hannah Collins, Viraj A. Master, Haydn T. Kissick, Milton Williams, Colleen Lewis, Amir Ishaq Khan, R. D. Harvey, Julie M. Shabto, Taofeek K. Owonikoko, Mehmet Akce
Publikováno v:
Annals of Oncology. 29:viii42
Autor:
Viraj A. Master, Bassel F. El-Rayes, Mehmet Asim Bilen, Olatunji B. Alese, Taofeek K. Owonikoko, Bradley C. Carthon, S.S. Ramalingam, Christina Wu, Dylan J. Martini, Conor E. Steuer, Ragini R. Kudchadkar, Hannah Collins, R. D. Harvey, Julie M. Shabto, Haydn T. Kissick, Colleen Lewis, Walid L. Shaib, David H. Lawson, Yingzi Liu, Mehmet Akce
Publikováno v:
Annals of Oncology. 29:viii433